2017
Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer
Mougalian SS, Epstein LN, Jhaveri AP, Han G, Abu-Khalaf M, Hofstatter EW, DiGiovanna MP, Silber ALM, Adelson K, Pusztai L, Gross CP. Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer. JCO Clinical Cancer Informatics 2017, 1: 1-10. PMID: 30657377, DOI: 10.1200/cci.17.00015.Peer-Reviewed Original ResearchConceptsAdverse effectsEndocrine therapyClinical trialsBreast cancerFrequency of AEsMedication-related adverse effectsTherapy-related adverse effectsBidirectional Text MessagingEndocrine therapy adherenceAdjuvant endocrine therapyMajority of patientsMedical record reviewSevere adverse effectsText message systemConsecutive patientsVaginal symptomsRecord reviewHot flashesTherapy adherenceClinic nursesHistorical controlsPatient acceptanceProvider teamGeneral populationPatients
2016
Patient preferences regarding incidental genomic findings discovered during tumor profiling
Yushak ML, Han G, Bouberhan S, Epstein L, DiGiovanna MP, Mougalian SS, Sanft TB, Abu-Khalaf MM, Chung GG, Stein SM, Goldberg SB, Pusztai L, Hofstatter EW. Patient preferences regarding incidental genomic findings discovered during tumor profiling. Cancer 2016, 122: 1588-1597. PMID: 26970385, DOI: 10.1002/cncr.29951.Peer-Reviewed Original ResearchConceptsIncidental findingTumor profilingGermline variantsAmbulatory oncology clinicsMajority of patientsStandard of careTumor profiling testsOncology clinicPreventable diseaseFamily historyPatient tumorsInformation patientsPreventable illnessPatientsDisease variablesUnpreventable diseaseUncertain significanceDisclosure preferencesCancerFrequent concernTumorsIllnessProfiling testsDiseaseCurrent study
2009
Eradication of Axillary Lymph Node Metastases Occurs in 74% of Patients Receiving Neoadjuvant Chemotherapy with Concurrent Trastuzumab for HER2 Positive Breast Cancer.
Dominici L, Negron Gonzalez V, Buzdar A, Lucci A, Mittendorf E, Pusztai L, Krishnamurthy S, Le-Petross H, Babiera G, Bedrosian I, Meric-Bernstam F, Hunt K, Valero V, Kuerer H. Eradication of Axillary Lymph Node Metastases Occurs in 74% of Patients Receiving Neoadjuvant Chemotherapy with Concurrent Trastuzumab for HER2 Positive Breast Cancer. Cancer Research 2009, 69: 1086-1086. DOI: 10.1158/0008-5472.sabcs-09-1086.Peer-Reviewed Original ResearchAxillary pathologic complete responseTrastuzumab-based neoadjuvant chemotherapyPathologic complete responseDisease-free survivalHER2-positive breast cancerHER2-positive diseaseResidual axillary diseaseNeoadjuvant chemotherapyPositive breast cancerAxillary metastasesPCR groupAxillary diseasePositive diseaseBreast cancerComplete axillary lymph node dissectionAxillary lymph node dissectionAxillary lymph node metastasisComplete pathologic responseLymph node dissectionKaplan-Meier methodMajority of patientsKaplan-Meier analysisLymph node metastasisEstrogen receptor statusConcurrent trastuzumab
1998
Daily Oral Etoposide in Patients With Heavily Pretreated Metastatic Breast Cancer
Pusztai L, Walters R, Valero V, Theriault R, Hortobagyi G. Daily Oral Etoposide in Patients With Heavily Pretreated Metastatic Breast Cancer. American Journal Of Clinical Oncology 1998, 21: 442-446. PMID: 9781596, DOI: 10.1097/00000421-199810000-00004.Peer-Reviewed Original ResearchConceptsGrade 4 toxicityMetastatic breast cancerSignificant hematologic toxicityOral etoposideBreast cancerGrade 2Hematologic toxicityDaily oral etoposideFourth-line agentZubrod performance statusPercent of patientsPhase II studyMajority of patientsGreater thrombocytopeniaNeutropenic feverStable diseasePrevious therapyRadiologic evidenceII studyMedian durationPartial responsePerformance statusMedian ageMore regimensSevere anemiaHigh-dose chemotherapy: how resistant is breast cancer?
Pusztai L, Hortobagyi G. High-dose chemotherapy: how resistant is breast cancer? Drug Resistance Updates 1998, 1: 62-72. PMID: 17092798, DOI: 10.1016/s1368-7646(98)80216-1.Peer-Reviewed Original ResearchHigh-dose chemotherapyClinical drug resistanceBreast cancerDrug resistancePartial responseClinical patternResponse rateComplete response rateHigh-dose therapyInitial complete responseObjective response rateStandard-dose chemotherapyDifferent clinical patternsMajority of patientsPrimary drug resistanceStem cell supportHigh cure ratesDrug-resistant clonesInduction therapyInitial chemosensitivityPathologic resistanceStable diseaseCancer dieOverall survivalComplete response